Vyant Bio, trading under the symbol VYNT, is a biotechnology company specializing in advanced phenotypic screening and human cell–based drug discovery platforms. The company leverages proprietary high-content imaging, digital pathology and epigenetic profiling to deliver in vitro and ex vivo models that more closely mirror human disease biology. Vyant Bio’s service offerings span from target identification and assay development to lead optimization and safety assessment, providing pharmaceutical and biotechnology clients with tools designed to accelerate preclinical research.
Central to Vyant Bio’s capabilities is its suite of integrated platforms, including three-dimensional organotypic cultures, precision-cut tissue slices and Disease in a Dish™ workflows. These platforms support research across a diverse range of therapeutic areas, including oncology, immunology, neuroscience and rare diseases. By combining induced pluripotent stem cell (iPSC)-derived models with tissue banking and multiplexed imaging, the company offers customized screening solutions and translational biomarkers that inform go/no-go decisions early in the development process.
Founded in 2001 and rebranded as Vyant Bio in 2020, the company is headquartered in Durham, North Carolina, with additional research and service facilities in Europe and the Asia-Pacific region. Over its two decades of operation, Vyant Bio has formed strategic collaborations with global pharmaceutical firms, contract research organizations and academic institutions. These partnerships have bolstered the company’s ability to validate novel therapeutic targets and expand its repository of human cell and tissue models.
Vyant Bio is guided by an experienced leadership team with deep roots in drug discovery and life-science innovation. President and Chief Executive Officer Dr. David A. Mack brings more than 20 years of industry and academic research experience, while Chief Scientific Officer Dr. Julia Z. Hart oversees the company’s R&D strategy. This seasoned management bench, supported by a board of directors with backgrounds in biotechnology and healthcare investment, drives Vyant Bio’s mission to de-risk drug development through human-relevant biology.
AI Generated. May Contain Errors.
